Skip to main content

Table 5 Relation of TLR4 genotypes versus demographic, clinical, and outcome data in vitiligo group 1 (below 18 years) patients

From: TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

SNPs rs1927914 rs1927911 rs11536858
CC
N/%
CT
N/%
TT
N/%
CC
N/%
CT
N/%
TT
N/%
AA
N/%
AG
N/%
GG
N/%
Sex M/F 0.20/0.03 0.20/0.15 0.60/0.81 0.10/0.15 0.80/0.69 0.10/0.15 0.20/0.24 0.70/0.57 0.10/0.18
p 0.13 0.66 0.15 1.0 0.53 1.0 1.0 0.48 1.0
Course Regressive/Progressive 0.00/0.13 0.00/0.13 1.00/0.73 0.00/0.17 1.00/0.61 0.00/0.22 0.00/0.22 1.00/0.70 0.00/0.09
p 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Psychiatric trauma +/− 0.33/0.09 0.00/0.14 0.67/0.76 0.00/0.19 0.67/0.62 0.33/0.19 0.00/0.24 1.00/0.67 0.00/0.09
p 1.0 1.0 1.0 1.0 1.0 0.52 1.0 0.53 1.0
Alopecia +/− 1.00/0.09 0.00/0.13 0.00/0.78 0.00/0.17 1.00/0.60 0.00/0.22 0.00/0.22 1.00/0.69 0.00/0.09
p 0.13 1.0 0.25 1.0 1.0 1.0 1.0 1.0 1.0
FH of vitiligo +/− 0.25/0.10 0.25/0.10 0.50/0.80 0.25/0.15 0.50/0.65 0.25/0.20 0.00/0.25 1.00/0.65 0.00/0.10
p 0.44 0.44 0.25 0.54 0.62 1.0 0.54 0.28 1.0
FHAIDs +/− 0.00/0.14 0.50/0.09 0.50/0.77 0.50/0.14 0.00/0.68 0.50/0.18 0.00/0.23 1.00/0.68 0.00/0.09
p 1.0 0.24 0.45 0.31 0.13 0.38 1.0 1.0 1.0
Remission +/− 0.29/0.06 0.14/0.12 0.57/0.85 0.43/0.06 0.43/0.71 0.14/0.24 0.29/0.18 0.57/0.77 0.14/0.06
p 0.19 1.0 0.31 0.06 0.36 1.0 0.61 0.37 0.51
Type Segmental/Nonsegmental 0.00/0.15 0.00/0.15 0.00/0.30 0.00/0.20 0.75/0.60 0.20/0.20 0.00/0.25 1.00/0.65 0.00/0.10
p 1.0 1.0 0.54 1.0 1.0 1.0 0.54 0.28 1.0
  1. M/F male/female, R/P regressive/progressive, Seg/Nonseg segmental/nonsegmental, FH family history, FHAIDs family history of auto-immune diseases, p value significant if < 0.05
  2. Fischer Exact test: no significant associations were detected